Literature DB >> 9474717

Surgical treatment of trigeminal neuralgia.

R Brisman.   

Abstract

Patients with medically intractable trigeminal neuralgia characterized by paroxysmal, triggered, trigeminally distributed pain are excellent candidates for neurosurgical intervention, which can not only relieve the pain of trigeminal neuralgia, but also eliminate the unpleasant side effects of medicines used to treat it. The two major neurosurgical choices are percutaneous denervation and microvascular decompression (MVD). Percutaneous denervation is done best when the surgeon has available radiofrequency and glycerol and uses one, the other, or both depending on technical circumstances that pertain to each patient. The percutaneous denervation is less likely than MVD to cause death, stroke, facial weakness, or hearing loss, but more likely to be associated with recurrence or dysesthesias. Patients with multiple sclerosis, medical illness, or who are elderly are much better candidates for percutaneous denervation. For any patient, a number of other factors also must be considered before deciding on a particular procedure. These include response to previous interventions, ability to tolerate carbamazepine, risk tolerance for various complications, preference regarding duration of hospital stay and postoperative recovery, presence of pain outside the trigeminal distribution, and findings on a high resolution magnetic resonance imaging (MRI) scan.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9474717     DOI: 10.1055/s-2008-1040950

Source DB:  PubMed          Journal:  Semin Neurol        ISSN: 0271-8235            Impact factor:   3.420


  5 in total

1.  Advanced age as a contraindication to microvascular decompression for drug-resistant trigeminal neuralgia: evidence of prejudice?

Authors:  Paolo Ferroli; Francesco Acerbi; Massimo Tomei; Giovanni Tringali; Angelo Franzini; Giovanni Broggi
Journal:  Neurol Sci       Date:  2009-10-06       Impact factor: 3.307

2.  Evaluation of surgical procedures for trigeminal neuralgia.

Authors:  K S Ong; S B Keng
Journal:  Anesth Prog       Date:  2003

3.  Dosimetric analysis of trigeminal nerve, brain stem doses in CyberKnife radiosurgery of trigeminal neuralgia.

Authors:  H Sudahar; P G G Kurup; V Murali; J Velmurugan
Journal:  J Med Phys       Date:  2012-07

4.  Intravenous immunoglobulin in the treatment of primary trigeminal neuralgia refractory to carbamazepine: a study protocol [ISRCTN33042138].

Authors:  Andreas Goebel; Andrew Moore; Rosamund Weatherall; Norbert Roewer; Robert Schedel; Guenter Sprotte
Journal:  BMC Neurol       Date:  2003-01-30       Impact factor: 2.474

5.  Perioperative and long-term operative outcomes after surgery for trigeminal neuralgia: microvascular decompression vs percutaneous balloon ablation.

Authors:  W Scott Jellish; William Benedict; Kevin Owen; Douglas Anderson; Elaine Fluder; John F Shea
Journal:  Head Face Med       Date:  2008-07-02       Impact factor: 2.151

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.